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ABSTRACT
Background and the purpose of the study: The purpose of the present investigation was to 
characterize, optimize and evaluate microballoons of Propranolol hydrochloride and to increase 
its boioavailability by increasing the retention time of the drug in the gastrointestinal tract.
Methods: Propranolol hydrochloride-loaded microballoons were prepared by the non-aqueous  
O/O emulsion solvent diffusion evaporation method using Eudragit RSPO as polymer. It was 
found that preparation temperature determined the formation of cavity inside the microballoon 
and  this  in  turn  determined  the  buoyancy.  Microballoons  were  subjected  to  particle  size 
determination, micromeritic properties, buoyancy, entrapment efficiency, drug loading, in vitro 
drug release and IR study. The correlation between the buoyancy, bulk density and porosity of 
microballoons were elucidated. The release rate was determined in simulated gastric fluid (SGF) 
of pH 1.2 at 37±0.5 °C.  
Results: The microballoons presented spherical and smooth morphologies (SEM) and were 
porous due to presence of hollow cavity. Microballoons remained buoyant for >12 hrs for the 
optimized formulation. The formulation demonstrated favorable in vitro floating and release 
characteristics. The encapsulation efficiency was high. In vitro dissolution kinetics followed 
the Higuchi model. The drug release from microballoons was mainly controlled by diffusion 
and showed a biphasic pattern with an initial burst release, followed by sustained release for 12 
hrs. The amount of the drug which released up to 12 hrs was 82.05±0.64%. Statistical analysis 
(ANOVA) showed significant difference (p < 0.05) in the cumulative amount of drug released 
after 30 min, and up to 12 hrs from optimized formulations. 
Conclusion: The designed system for propanolol would possibly be advantageous in terms of 
increased bioavailability and patient compliance.
Keywords: Floating drug delivery system, O/O emulsion Solvent diffusion/evaporation method, 
Eudragit RS PO, Buoyancy.
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INTRODUCTION
The preferred route for the administration of most 
drugs  is  gastrointestinal  tract.  Most  of  the  orally 
administered dosage forms have several physiological 
limitations, such as gastrointestinal (GI) transit time, 
incomplete  drug  release  from  devices  and  short 
residence time of the pharmaceutical dosage forms 
in the absorption region of GI tract. These factors 
lower the bioavailability of sustained-release dosage 
forms and even if slow release of drug is attained, 
the drug released after passing the absorption site is 
not utilized, thus lowering the efficacy of the drug 
(1).
To overcome this problem several attempts have been 
made to develop oral dosage forms having prolonged 
retention time in the stomach to extend the duration 
of drug delivery. Several gastrointestinal targeting 
dosage forms, including intragastric floating, high 
density, bioadhesive, swelling and magnetic systems 
have been developed (2-4).
One approach which has been used successfully is 
floating drug delivery systems (FDDS). While the 
system floats over the gastric contents, the drug is 
released slowly at the desired rate. Such systems 
are best suited for drugs having a better solubility 
in acidic environment and also for the drugs having 
specific site of absorption in the upper part of the 
small intestine (5,6). While both single and multiple 
unit systems have been developed, a disadvantage 
of  single  unit  system  is  the  high  variability  of 
gastrointestinal transit time, due to its all-or-nothing 
gastric emptying process. Therefore, a multiple-unit 
floating system that distributes widely throughout 
the gastrointestinal tract has been sought.  Sato et al. 
developed a multiple-unit intragastric floating system 
involving hollow microspheres (microballoons) with 
excellent  buoyant  properties  using  o/w  emulsion 
solvent  diffusion  method.  This  gastrointestinal 
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transit-controlled preparation is designed to float on 
gastric juice with a specific density of less than 1 for 
prolonged period (2, 7). 
Microballoons are in a strict sense, spherical empty 
particles without core having internal hollow structure 
with air inside. Microballoons incorporating a drug 
dispersed  or  dissolved  throughout  particle  matrix 
have the potential for controlled release of drugs (8).
Certain  types  of  drugs  can  benefit  from  using 
gastroretentive  devices.  These  include:  1)  Drugs 
acting  locally  in  the  stomach;  2)  Drugs  that  are 
primarily absorbed in the stomach; 3) Drugs which 
are poorly soluble at an alkaline pH; 4) Drugs with 
a narrow window of absorption; 5) Drugs absorbed 
rapidly from the GI tract; and 6) Drugs that degrade 
in the colon (9).
Propranolol  hydrochloride  (PH),  a  non-selective 
beta-adrenergic  blocker,  has  been  widely  used  in 
the  treatment  of  hypertension,  angina  pectoris, 
pheochromocytoma  and  cardiac  arrhythmias.  Its 
short  biological  half-life  (3-5  hrs)  necessitates 
the  need  to  administer  the  drug  in  two  or  three 
doses of 40 to 80 mg per day. Such frequent drug 
administration  may  reduce  patient  compliance 
and  therapeutic  efficacy  (10).  The  bioavailability 
of  PH  after  oral  administration  is  approximately 
30%.  Co-administration  with  food  appears  to 
enhance  bioavailability  (11).  The  development  of 
gastroretentive controlled-release dosage forms thus 
would  clearly  be  advantageous.  Researchers  have 
formulated oral controlled-release products of PH 
by various techniques. Since, its site of absorption 
is the stomach, a dosage form that is retained in the 
stomach  would  increase  the  absorption,  improve 
drug  efficiency,  and  decrease  dose  requirements. 
Thus, the aim of the present investigation was to 
characterize, optimize and evaluate microballoons 
of PH for oral controlled drug delivery (11, 12).
Eudragit RSPO as a low-density polymer was used 
to  prepare  floating  PH  microballoons  because  it 
has  sustained  release  properties  with  low  water 
permeability, which results in enhanced floatability.
In the present study, floating microballoons of PH were 
prepared using an O/O emulsion solvent diffusion 
evaporation technique which is useful for stabilization 
of  drugs  and  to  improve  their  distribution.  This 
technique is suitable for encapsulating both lipophilic 
and hydrophilic drugs (8). Another advantage is the 
possibility of producing microballoons of required 
size range, porosities, and shapes. 
MATERIAL AND METHODS
Propranolol  hydrochloride  was  procured  as  a  gift 
sample  from  Kwality  Pharmaceuticals,  (Amritsar, 
India).  Eudragit®  RSPO  (Ammonio  Methacrylate 
Copolymer  Type  B)  was  also  procured  as  a 
gift  sample  from  Cadila  Pharmaceuticals  Ltd., 
(Ahemdabad,  India).  Dichloromethane  LR  was 
purchased from RFCL limited (New Delhi, India), 
and  Ethanol AR,  light  liquid  paraffin  oil  LR  and 
glycerol monostearate were purchased from S D Fine 
Chem limited, (Mumbai, India). All other chemicals 
were of analytical grade.
Preparation of microballoons  
Microballoons were prepared by the O/O emulsion 
solvent  diffusion  evaporation  method.  Weighed 
amounts  of  PH,  Eudragit  RSPO  and  glyceryl 
monostearate  (12.5%w/w)  were  dissolved  in  a 
mixture  of  dichloromethane  (10  ml)  and  ethanol 
(10 ml) at room temperature. The resulting solution 
of  PH  was  then  poured  dropwise  into  200  ml 
light liquid paraffin oil containing span 20 (0.2% 
v/v)  as  a  surfactant  with  constant  stirring  at  500 
rpm employing a 3-bladed propeller type agitator 
(REMI motors, Mumbai, India)  for 2 hrs at various 
temperatures of 30, 40 and 50°C. Residual organic 
solvents were evaporated using a rotary evaporator 
(Buchi rotavapour R II, Switzerland) for 20 min. at 
40°C.  The resulting microballoons were separated 
by filtration, freed from liquid paraffin oil by repeated 
washing  with  n-hexane  (4x50  ml)  and  finally  air 
dried over a period of 12 hrs (2, 8). 
 Variation of formulation factors
Different PH: Eudragit RSPO ratios (1:1, 1:2, 1:3, 
1:4 and 1:5) were used in order to find out the effect 
of drug: polymer ratio on physical characterization 
and buoyancy of microballoons. The effect of stirring 
speed (250, 500, and 750 rpm), concentrations of 
span 20 (0.2%, 0.3% and 0.4% v/v), the volume of 
processing medium (light liquid paraffin oil, 150, 
200 and 250 ml) and the deaggregating agent (5%, 
10%,  15%  w/w)  on  microballoons  characteristics 
were investigated.
Characterization of microballoons
Microballoon morphology
The morphology of the microballoons was studied 
by  scanning  electron  microscopy  (Philips  505, 
Holland).  SEM  requires  the  coating  of  the  dried 
sample with a conductive material usually gold. The 
samples for SEM were prepared by lightly sprinkling 
the powder on a double-sided adhesive tape stuck to 
an aluminum stub. The stubs were then coated with 
a mixture of gold and palladium to a thickness of 
200-500 Å under an argon atmosphere using a gold 
sputter module (POLARON, SEM coating system) in 
a high-vacuum evaporator at 1.4KV voltage, 18 mA 
current and 10-2 mbar pressure. The coated samples 
were then randomly scanned and photomicrographs 
were taken with SEM. To investigate the internal 
morphology, the hollow microspheres were dissected 
with a blade (13, 14).
  
Micromeritic Properties
Microballoons were characterized for micromeritic 
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density and porosity (13, 15).
Particle size analysis
Particle  size  measurements  were  carried  out  on 
an image analysis system. An optical microscope 
connected  with  a  digital  camera  (YOKO  CCD 
Camera, Taiwan) was used to produce pictures of the 
microballoons. The particle size distribution of each 
formulation was measured by determination of the 
diameter of 100 randomly selected microballoons 
using the MEDICAL PRO software (16). 
Bulk density, True density and Porosity
Bulk density was calculated from the formula given 
below (17):
Bulk density Pb =
Mass of microballoons
Bulk volume of microballoons
True density (Pt) was determined by using a Helium 
air densitometer (No. 1305, Shimadzu, Japan).
Porosity was calculated as follows:
Porosity ε = [1- Pb/Pt] x 100
                                                                                   
 Interaction studies
The IR spectra were recorded for PH, Eudragit RSPO, 
physical  mixture  and  drug-loaded  microballoons 
using KBr pellets by FTIR-8400s (Shimadzu, Japan). 
The scanning range was 4000 cm-1 - 400 cm-1.
Process yield
The  prepared  microballoons  were  collected  and 
weighed. The measured weight was divided by the total 
amount  of  all  non-volatile  components  which  were 
used for the preparation of the microballoons (18). 
% Yield =
Actual weight of the product
 × 100    Total weight of excipient and drug
Entrapment Efficiency (E.E.) and drug loading
Microballoons equivalent to 50 mg of the drug were 
taken for evaluation. The amount of drug entrapped 
was estimated by crushing the microballoons and 
extracting  with  aliquots  of  0.1N  HCl  of  pH  1.2 
repeatedly (3x10ml). The extract was transferred to 
a 100 ml volumetric flask and the volume was made 
up to 100ml using 0.1N HCl of pH 1.2. The solution 
was filtered and the absorbance was measured after 
suitable  dilution  spectrophotometrically  (UV-1700 
Pharmaspec  Shimadzu,  Japan)  at  289  nm  against 
appropriate blank. The amount of the drug entrapped 
in the microballoons was calculated by the following 
formula (18): 
E.E. =
Amount of drug actually present
×100
Theoretical drug load expected
Drug loading =
Weight of drug in 
microballoons
× 100
Weight of microballoons 
recovered
In vitro buoyancy
Microballoons (100 mg) were spread over the surface 
of a USP dissolution apparatus (type II) filled with 
900 ml simulated gastric fluid of pH 1.2  containing 
0.02% Tween 20. The medium was agitated with a 
paddle rotating at 100 rpm for 12 hrs. The floating and 
the settled portions of microballoons were recovered 
separately.  The  microballoons  were  air  dried  and 
weighed.  Percentage  buoyancy  was  calculated 
as the ratio of the mass of the microballoons that 
remained floating and the total mass of the taken 
microballoons  (2).  Buoyancy  was  recorded  as  a 
function of temperature, drug polymer ratio, stirring 
time, emulsifier concentration, volume of processing 
medium and deaggregating agent. Observations are 
recorded in tables 1 and 2.  
In-vitro drug release study
The drug release study was carried out using USP 
rotating  paddle  apparatus  (Veego,  DA-6DR  USP 
Standards) at 37 ± 0.5 ºC and at 100 rpm using 900 
ml of simulated gastric fluid of pH 1.2 containing 
0.02%  Tween  20  as  a  dissolution  medium. 
Microballoons  equivalent  to  50  mg  of  PH  were 
used for the test. Five ml of the sample solution 
was  withdrawn  at  predetermined  time  intervals, 
filtered  through  filter  paper,  diluted  suitably  and 
analyzed  spectrophotometrically  using  UV-VIS 
spectrophotometer  (Should  be  eliminated,  it  has 
been repeated) at a wavelength of 289 nm. Equal 
amount of fresh dissolution medium was replaced 
immediately after withdrawal of the test sample to 
maintain the sink condition. All experiments were 
performed in triplicates (19).  
Drug release kinetics
The  drug  release  kinetics  was  studied  by  various 
kinetic models such as Korsmeyer-peppas, Higuchi, 
first order and zero order plots. The best fit model 
was confirmed by the value of correlation coefficient 
near to 1 (10, 20). 
Statistical analysis of dissolution data
The  mean  readings  of  in  vitro  release  data  of 
Propranolol hydrochloride from microballoons of 
formulations MB1, MB2, MB3, MB4, and MB5 
were statistically analyzed by one-way analysis 
of variance (ANOVA) with post test (Newman-
Keuls Multiple Comparison Test) at two different 
time  intervals  30  min  and  12  hrs.  Differences 
between in vitro drug release of formulations were 
defined as statistically significant when P<0.05. 
Calculations  were  performed  using  GraphPad 
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Stability testing 
Microballoons were hermetically sealed in glass 
bottles and stored for 3 months at 4±0.5ºC, room 
temperature  and  40±1ºC  and  75%  RH  as  per 
ICH guidelines. After every 15 days, one bottle 
was  used  for  evaluation.  The  microballoons 
were evaluated for physical appearance and drug 
content (21).
RESULTS AND DISCUSSION
PH,  due  to  its  hydrophilicity,  is  likely  to  be 
preferentially partitioned into the aqueous medium, 
leading  to  low  entrapment  efficiency,  when 
encapsulated using aqueous phase as the processing 
medium. The solvent system selected for the present 
study was a mixture of ethanol and dichloromethane 
in the ratio of 1:1. Span 20 was used as surfactant 
for stabilization of emulsification process. Glyceryl 
monostearate was used as deaggregating agent.
Microballoons prepared at 30°C had porous surface 
but  were  so  brittle  as  to  crumble  upon  touching. 
They also displayed lower buoyancies (25.34±1.23% 
after 12 hrs) probably due to the easy penetration of 
simulated gastric fluid of pH 1.2 through the porous 
surface (Table 1). Microballoons prepared at 40°C 
were  spherical  in  shape  and  smoother  than  those 
prepared  at  30°C.  They  showed  better  buoyancy 
(74.43±3.46%).  Microballoons  prepared  at  50°C 
showed  poor  buoyancy  due  to  its  non-porous 
nature which could be due to rapid evaporation of 
dichloromethane at temperatures beyond its boiling 
point of 40.2°C. Thus, the optimized temperature 
for the formulation of microballoons was selected 
as 40°C.
Microballoons were  prepared with  different drug: 
polymer ratio (1:1, 1:2, 1:3, 1:4, 1:5), keeping all 
other parameters constant at 40°C. The mean particle 
size of the microballoons increased significantly by 
decrease in drug polymer ratio (22) and was in the 
range of 286±4.61 -594±7.46 µm (Table 2A). 
The drug entrapment efficiency increased initially 
from  44.16±4.32  to  80.40±1.75  %  w/w  by  the 
decrease in drug polymer ratio up to 1:4 after which 
it decreased.  A larger particle size was observed at 
drug: polymer ratio of 1:5 (594.79±7.46 µm). Since 
drug  entrapment,  buoyancy  and  particle  size  are 
dependent on factors like stirring speed, emulsifier 
concentration and deaggregating agent, an increase 
in  polymer  concentration  may  have  resulted  in  a 
shift in the equilibrium between these factors, which 
was evident by a reduction in drug entrapment, per 
cent process yield, per cent drug loading and reduced 
buoyancy. Thus, the optimized drug: polymer ratio 
was selected as 1:4. 
Microballoons were prepared by keeping all other 
parameters  constant,  at  three  different  speeds  i.e. 
250, 500, 750 rpm. Highest entrapment efficiency 
was observed with the stirring speed of 500 rpm 
having desired particle size i.e. 575±6.22 µm and 
maximum drug entrapment i.e. 80.40±1.75 % w/w 
(Table 2B).
Microballoons were then optimized for emulsifier 
concentrations  (0.2%,  0.3%  and  0.4%  v/v).  At 
0.2  %v/v  concentration  of  span  20,  an  average 
particle size of 575±6.22µm and maximum % drug 
entrapment  efficiency  of  80.40±1.75%  w/w  was 
obtained (Table 2C). The mean microballoon size, 
buoyancy  and  drug  entrapment  efficiency  were 
also  found  to  decrease  by  increase  in  emulsifier 
concentration. This may be due to the fact that the 
increase in emulsifier concentration proportionately 
increases  miscibility  of  ethanol  with  light  liquid 
paraffin (processing medium), which may increase 
the extraction of drug into the processing medium. 
The buoyancy could have decreased due to tightening 
of  polymeric  network,  leading  to  microballoon 
shrinkage  with  an  increase  in  the  concentration 
of  emulsifier  (23,  24).  Microballoons  were  then 
optimized for volume of processing medium (150, 
200 and 250 ml). The highest entrapment efficiency 
was observed with 200 ml of processing medium 
having desired particle size i.e. 575±6.22 µm and 
maximum drug entrapment i.e. 80.40±1.75 % (Table 
2D). Decrease in volume of processing medium (150 
ml) resulted in low drug entrapment and buoyancy 
which could be due to aggregation of polymer due to 
its increased concentration. An increase in volume 
of processing medium (250 ml) resulted in low drug 
entrapment  because  as  the  volume  of  processing 
medium  increased,  collision  induced  aggregation 
reduced, yielding smaller microballoons with low 
buoyancy  due  to  lesser  porosity. This  could  also 
be the reason for higher drug extraction in to the 
processing medium resulting in lower entrapment 
efficiency.
Microballoons  were  then  optimized  for  different 
concentrations of deaggregating agent at 40°C. At 
10 %w/w concentration of glyceryl monostearate, 
an  average  particle  size  of  612.23±5.56  µm 
and  maximum  %  drug  entrapment  efficiency  of 
80.34±1.34% w/w was obtained (Table 2E). As the 
concentration of deaggregating agent was increased, 
the particle size decreased and the drug entrapment 
increased.  However,  there  was  no  significant 
difference when concentration was increased from 
10% to 15% w/w. 
The average particle size of the optimized batch was 
found to be 575±6.22 µm (Table 2). The bulk density 
values ranged from 0.6682±0.024 to 0.4433±0.015 
gm/cm3  while  their  true  densities  ranged  from 
1.0169±0.0035  to  1.0018±0.0031  gm/cm3.The 
porosity  of  all  the  microballoon  formulations 
was found to be in the range from 34.29±0.45 to 
55.72±0.51 (Table 3). The optimized batch showed 
excellent porosity which is necessary for the longer 
floatability of microballoons.
The  shape  and  surface  morphology  of  the 
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in figures 1a-d which confirms that the drug-loaded 
microballoons  were  spherical  and  had  a  smooth 
surface. The characteristic internal structure of the 
microballoon, a hollow cavity enclosed in a rigid 
shell was clearly evident (Fig 1). Diffusion of ethanol 
through the solution, accompanied by simultaneous 
evaporation of dichloromethane may have resulted 
in formation of cavity. 
There was no drug- excipient interaction, as it was 
confirmed  by  IR  spectra  of  pure  drug  as  well  as 
microballoons since similar peaks were obtained in 
both the cases. 
Drug  loading  and  process  yield  of  the  optimized 
batch  was  found  to  be  16.13±1.18%  w/w  and 
90.42±1.25 % respectively as it is shown in table 2. 
The higher drug loading typically results in lower 
encapsulation efficiency due to higher concentration 
gradients resulting in the drug diffusing out of the 
polymer/solvent droplets into the external processing 
medium.
In vitro percentage of buoyancy for the optimized 
batch was satisfactory which may be attributed to 
the low bulk density and optimum porosity of the 
microballoons (13, 25). Porosity of microballoons 
increased as cavity volume increased (Fig 2). The 
buoyancy of the optimized batch was found to be 
formulation (MB0) prepared at temperature 30°C 40°C 50°C
Buoyancy (%) after 12 hours 25.34±1.23 74.43±3.46 16.58±62
Table 1. Effect of temperature on buoyancy.
Optimization
 parameters
Mean Particle size 
(µm)
E.E.
(%w/w)
% Process Yield
Drug loading
(%w/w)
Buoyancy (%) 
after 12 hrs
Inference (Based on E.E. 
(%w/w) and % buoyancy)
A) Drug: polymer ratio
1:1 (MB1)
1:2 (MB2)
1:3 (MB3)
1:4 (MB4) #
1:5 (MB5)
286.14±4.61
328.25±6.83
436.33±8.64
575.21±6.22
594.79±7.46
44.16±4.32
66.22±3.12
70.07±3.45
80.40±1.75
76.03±3.45
66.36±4.78
74.13±3.65
80.80±3.85
90.42±1.25
86.11±3.12
25.21±2.45
24.64±2.12
19.01±2.48
16.13±1.18
13.74±2.02
34.75±4.62
46.34±2.95
73.66±3.88
87.43±1.61
84.25±3.20
Very low
Very low
Low 
High
Good
B) Stirring speed (rpm)
250 (MBS1)
500 (MBS2) #
750 (MBS3)
732.62±8.57
575.21±6.22
189.74±5.57
72.73±3.62
80.40±1.75
70.04±5.02
  81.98±3.75
  90.42±1.25
  78.95±4.78
15.87±1.75
16.13±1.18
 15.71±1.66
 82.54±3.89
 87.43±1.61
 74.43±3.46
Low
High
Low 
C) Emulsifier conc. (%v/v)
0.2 (MBE1) #
0.3 (MBE2)
0.4 (MBE3)
575.21±6.22
454.45±8.54
387.19±5.62
80.40±1.75
74.91±3.69
73.10±3.87
  90.42±1.25
  85.60±3.45
  82.41±4.12
16.13±1.18
15.69±1.13
15.79±1.77
 87.43±1.61
 79.23±3.48
 77.18±2.89
High
Low 
Low 
D) Volume of processing Medium (ml)
150 (MBV1)
200 (MBV2) #
250 (MBV3)
752.16±7.35
575.21±6.22
412.89±4.87
76.22±2.94
80.40±1.75
71.11±2.68
  86.03±2.82
  90.42±1.25
  79.95±3.06
15.81±1.23
16.13±1.18
16.30±1.31
 84.14±3.51 
 87.43±1.61
 78.12±2.91
Good 
High 
Low 
E) Deaggregating agent (%w/w)
5  (MBD1)
10 (MBD2) # 
15 (MBD3)
678.15±7.23
612.23±5.56
594.44±6.74
68.74±2.54
80.34±1.34
80.50±2.31
 75.02±2.55
 90.14±1.19
 90.11±2.24
17.50±1.45
16.15±1.07
15.59±1.23
 76.16±2.16
 87.54±1.41
 87.12±1.98
Low 
High 
High 
*all experiments were performed in triplicate (n=3), # optimized formulation
Table 2. Effect of various processing parameters on Entrapment Efficiency (E.E.) and buoyancy*. Microballoons of propranolol hydrochloride 198
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Figure 1. SEM Photomicrographs (a) Cross-section of Microballoons showing hollow structure 
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at 750 rpm. 
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87.43±1.61 % when the average particle size was 
575.21±6.22µm. 
The microballoons sank completely within 24 to 30 
hrs. As the drug diffused out from the microballoon, 
small  pores  were  formed  in  the  system  which 
allowed surrounding medium to enter and fill up the 
void spaces, thereby increasing weight.
In  vitro  drug  release  studies  were  performed  in Porwal et al / DARU 2011 19 (3) 193-201 199
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Figure 3 In-Vitro release profile of Propranolol HCl Microballoons in SGF pH 1.2 (n=3) 
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Figure 3. In vitro release profile of Propranolol HCl Microballoons in SGF pH 1.2 (n=3) 1:1-1:5 indicates drug polymer ratios.
Drug: Polymer ratio
Bulk density 
(gm/cm3)
True density 
(gm/cm3)
Porosity (%)
Buoyancy (%) 
after 12 hrs
Inference (porosity (%) 
and % buoyancy)
 1:1  (MB1)
 1:2  (MB2)
 1:3  (MB3)
 1:4  (MB4) #
 1:5  (MB5)
0.6682±0.024
0.5917±0.019
0.5294±0.021
0.4433±0.015
0.4865±0.022
1.0169±0.0035
1.0102±0.0039
1.0016±0.0041
1.0012±0.0024
1.0018±0.0031
34.29±0.45
41.42±0.84
47.14±0.67
55.72±0.51
51.43±0.59
34.75±4.62
46.34±2.95
73.66±3.88
87.43±1.61
84.25±3.20
Very low
Very low
Low
High        
 Good
*All experiments were performed in triplicate (n=3), # optimized formulation.
Table 3. Effect of bulk density and porosity on buoyancy of microballoons*.
simulated gastric fluid of pH 1.2 for 12 hrs. The 
cumulative release of drug significantly decreased 
with increase in polymer concentration (Fig 3).
The in vitro release profile was biphasic with an initial 
burst release (16.05±0.94%) upto 0.5 hour attributed 
to  surface  associated  drug,  followed  by  a  slower 
release phase as the entrapped drug slowly diffused 
into the release medium (Fig 3). Percentage of the 
drug released up to 12 hrs was 82.05±0.64. There was 
sustained release of drug at a constant rate.
The calculated regression coefficients for zero order, 
first  order  and  Higuchi  models  were  found  to  be 
0.976, 0.990, and 0.987 respectively.  The in vitro 
drug release of propranolol HCl microballoons was 
best  explained  by  first  order  equation  as  the  plot 
showed the highest linearity, followed by Higuchi’s 
model. The ‘n’ value for Korsmeyer-Peppas equation 
was found to be 0.445 indicating diffusion controlled 
drug release.       
When  the  in  vitro  release  data  of  formulation 
MB4  (drug  polymer  ratio  1:4)    was  compared 
with  formulations  MB1,  MB2,  MB3,  and  MB5 
by  one-way  ANOVA  (Newman-Keuls  multiple 
comparison) test, the in vitro release in SGF (pH 
1.2)  from  MB4  after  30  min  was  found  to  be 
significant  (P<0.0002).  Significant  differences 
(p<0.0001) were also observed for the amount of 
drug released after 12 hrs for the same formulation 
MB4. MB3 was found to be significantly different 
from MB1, MB2 and MB5. On the basis of other 
optimization parameters, MB4 was considered to 
be the optimized batch.
From the results of stability studies (Table 4) it 
appears that for adequate shelf life of optimized 
Propranolol  hydrochloride  microballoons,  they 
should be stored in cool (4-5ºC) and dry place.
Thus, the prepared microballoons may prove 
to  be  potential  candidates  for  multiple-unit 
delivery devices adaptable to any intragastric 
condition. Microballoons of propranolol hydrochloride 200
S. No.
Sampling 
interval (days)
% Residual Drug Content Mean±S.D. (n=3) Physical appearance
4±0.5°C Room temp.
40±0.5°C & 
75% RH
4±0.5°C Room temp.
40±0.5°C & 
75% RH
1 15 99.64±0.11 99.38±0.12 - + + -
2 30 99.08±0.07 98.77±0.15 - + + -
3 45 98.67±0.09 98.22±0.11 - + + -
4 60 98.28±0.12 97.61±0.09 - + + -
5 75 97.89±0.06 97.04±0.14 - + + -
6 90 97.51±0.08 96.48±0.08 - + + -
+ No change, - Clump formation
Table 4. Stability Data for propranolol hydrochloride microballoons at different temperatures.
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